wampetin | 89824-26-0

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 香豆素及其衍生物
• 英文名称: wampetin
• 英文别名: 9-[(Z)-3-methyl-4-(4-methyl-5-oxo-2H-furan-2-yl)but-2-enoxy]furo[3,2-g]chromen-7-one
• CAS: 89824-26-0
• 化学式: C₂₁H₁₈O₆
• 分子量: 366.37
• InChiKey: XVVBVBKVMMNZHB-XGICHPGQSA-N

物化性质

• 沸点：
  612.6±55.0 °C(Predicted)
• 密度：
  1.303±0.06 g/cm3(Predicted)
• 物理描述：
  Solid
• 熔点：
  78°C

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  75
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  wampetin 在 硫酸 作用下， 以 溶剂黄146 为溶剂， 反应 0.5h， 以6 mg的产率得到花椒毒醇
  参考文献：
  名称：

  Wampetin, a furocoumarin from Clausena wampi

  摘要：

  DOI：

  10.1016/0031-9422(83)80185-x

文献信息

• COMPOUND FOR USE IN THE TREATMENT AND/OR PREVENTION OF PARASITIC MEDIATED DISEASES
  申请人：LEEWARD PACIFIC PTE LTD

  公开号：US20190046503A1

  公开（公告）日：2019-02-14

  The present invention provides a compound belonging to furanocoumarin derivative having core structure (A) as given below, its pharmaceutically acceptable salt, isomer or a combination thereof for the treatment and/or prevention of a parasitic mediated disease. The present invention also provides a method for manufacturing and isolating said compound as well as method for treatment and prevention of parasitic mediated disease using said compound. In a preferred embodiment, the parasite is Plasmodium falciparum , the disease mediated by the said parasite is malaria and the furanocoumarin derivative having core structure (A) is Anisolactone.
• [EN] COMPOUND FOR USE IN THE TREATMENT AND/OR PREVENTION OF PARASITIC MEDIATED DISEASES<br/>[FR] COMPOSÉ POUR UNE UTILISATION DANS LE TRAITEMENT ET/OU LA PRÉVENTION DE MALADIES D'ORIGINE PARASITAIRE
  申请人：LEEWARD PACIFIC PTE LTD

  公开号：WO2017155465A1

  公开（公告）日：2017-09-14

  The present invention provides a compound belonging to furanocoumarin derivative having core structure (A) as given below, its pharmaceutically acceptable salt, isomer or a combination thereof for the treatment and/or prevention of a parasitic mediated disease. The present invention also provides a method for manufacturing and isolating said compound as well as method for treatment and prevention of parasitic mediated disease using said compound. In a preferred embodiment, the parasite is Plasmodium falciparum, the disease mediated by the said parasite is malaria and the furanocoumarin derivative having core structure (A) is Anisolactone.